Details are as follows:
(1) for1chronic hepatitis B patients over 8 years old. Because 18 years old, the thymus began to shrink and the cellular immune function declined.
(2) All kinds of primary or secondary T cell deficiency.
(3) Some autoimmune diseases (such as rheumatoid arthritis and systemic lupus erythematosus).
(4) Various diseases with low cellular immune function.
(5) Adjuvant treatment of tumor.
Extended data:
Matters needing attention
(1) This product plays a therapeutic role by enhancing the immune function of patients. Therefore, patients receiving immunosuppressive therapy (such as organ transplant recipients) should use this product with caution, unless the benefits of treatment obviously outweigh the risks.
(2) Patients with chronic hepatitis B should regularly check their liver function during treatment.
(3)/kloc-Use with caution in patients under 0/8 years old.
pharmacokinetics
Pharmacokinetic studies showed that thymopentin was rapidly degraded by protease and aminopeptidase in human plasma, with a half-life of about 30 seconds, while the retention time in abdominal cavity was 3.5-7 minutes longer than that in plasma. After 10 minute, 25% of human saliva could not be degraded. Although thymopentin is metabolized rapidly, it can act on target cells quickly after a single injection. Through the second messenger, the in vivo effect can last for days to weeks.
References:
Baidu encyclopedia-thymosin for injection